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S52 Journal of Thoracic Oncology Vol. 11 No. 2Sconclusively showed catheter position in the centre of
SPN (26 cases) NIR spectroscopy probe based forceps
were placed at the same place in order to gather tissue
information. Mean measurement time was less than one
minute after establishing ideal position. Results of
spectroscopy measurements from NIR spectroscopy
were obtained as differences between spectral charac-
teristics of normal tissue (same side, different lobe) to
SPN tissue.
Results: The results are expressed as sensitivity of NIR
spectroscopy towards EBUS navigated biopsies. Statisti-
cal analysis of the results showed very high sensitivity
for NIR spectroscopy in conﬁrmation of SPN tissue. From
26 EBUS positive visualisations of SPN there were 26
correct discriminations of SPN tissue, leading to 23
conclusive histological ﬁndings.
Conclusions: Every conﬁrmatory method brings
different information about tissue. EBUS describes vol-
ume of the SPN and gives valuable information about the
position of catheter in the SPN. NIR spectroscopy brings
information about biochemical/ optical characteristics of
the tissues. Prototype of intelligent NIR based forceps
showed good discriminative ability in the diagnosis of
SPN.* Due to unforeseen circumstance, this poster was not presented.Characterization of programmed cell
death-1 ligand (PD-L1) expression in
circulating tumor cells (CTCs) of lung
cancerRachel Krupa, David Lu, Ryon Graf,
Jessica Louw, Lyndsey Dugan,
Adam Jendrisak, Kelly Bethel, Yipeng Wang,
Dena Marrinucci, Ryan Dittamore Epic Sciences, San
Diego, CA
Introduction: The programmed cell death-1/pro-
grammed cell death-1 ligand (PD-1/PD-L1) pathway
plays a key role in tumor immune invasion. Emerging
literature suggests that PD-L1 over-expression on solid
tumor tissue, including lung cancer, is associated with
PD-1/PD-L1 immunotherapy efﬁcacy. Epic Sciences has
developed circulating tumor cells (CTCs) based PD-L1
assay, and we sought to evaluate the feasibility of
detecting PD-L1 biomarker in lung cancer CTCs.
Methods: 74 samples from newly diagnosed lung cancer
patients prior to therapy were recruited and blood
specimens were collected and shipped to Epic Sciences.
All nucleated cells were plated onto glass slides and
subjected to immunoﬂuorescence (IF) staining and CTCidentiﬁcation by ﬂuorescent scanners and algorithmic
analysis. CK(þ) CTCs(CKþ CD45- w/intact DAPI nuclei
and morphologically distinct), apoptotic CTCs (CKþ,
CD45-, non-intact nuclei), CTC Clusters (two or more
CTCs together) and CK(-) CTCs (CK-, CD45-, intact and
distinct) were identiﬁed. Samples were characterized
with PD-L1 IF to assess expression.
Results: Assays for the PD-L1 protein were developed
and speciﬁcity conﬁrmed utilizing Colo205 (negative
control) and H820 (high PD-L1 expression) cells spiked
into donor blood and run through the Epic Assay. Addi-
tionally, analysis of Colo205, A549, and SU-DHL-1 cell
lines show increased differential expression when cells
were exposed to Interferon gamma. PD-L1 protein
expression was visualized in CTCs of 15/74 (20%) pa-
tients with lung cancer. PD-L1 expression was seen in
CK(þ) CTCs, CK(-) CTCs, apoptotic CTCs, andCTCClusters.
Conclusion: PD-L1 protein assessment in CTC sub-
populations from lung cancer patients at diagnosis is
feasible on the Epic CTC platform. The test demonstrates
analytical sensitivity and speciﬁcity and may aid in the
identiﬁcation of patients suitable for clinical trial studies
with novel anti-PD-1 or anti-PD-L1 therapies. The
assessment of PD-L1 expression from a circulating
marker could enable longitudinal and pharmacodynamic
analysis in response to PD-1 axis blockade in patients.Validation of DNA methylation marker
SHOX2 and PTGER4 for detection of
lung cancer in plasmaAnne Schlegel, Oliver Hasinger,
Thomas König, Gunter Weiss Epigenomics AG,
Berlin, Germany
Introduction: Annual screening for lung cancer (LC)
with low-dose computed tomography (LDCT) has been
shown to reduce mortality in a speciﬁc group of high risk
individuals. At the same time some controversy builds
around the substantial rate of false positive ﬁndings of
the method. Thus, research focuses on two questions: 1)
Whom to screen? Additions to and reﬁnements of the
group of high risk individuals who potentially beneﬁt
from LDCT screening. 2) What to do with a nodule?
Distinguish a malignant nodule from a benign one. Here,
we report on a panel of two DNA methylation markers,
SHOX2 and PTGER4, with the potential to address either
or both of the aforementioned questions.
Material and Methods: A triplex real-time PCR assay
was developed to assess the level of methylated DNA of
genes SHOX2 and PTGER4 in bisulﬁte converted DNA
containing ACTB as internal control. DNA was extracted,
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samples utilizing a commercially available kit. In a case-
control design 149 specimens from lung cancer patients
and age-matched healthy individuals were evaluated.
The diagnostic performance was compared to the results
from a previously conducted training study on 151
specimens.
Data and Results: For the training study including 59 LC
subjects the performance of the marker panel reached
very high sensitivity (78–95%) at reasonable rates of false
positives (5–36%). The area under the receiver operating
characteristic (ROC) curve was AUC ¼ 0.91. This clinical
performance was conﬁrmed in a similar sized marker
validation study of an independent set of 149 patients. A
total of 49 LC cases and 100 age-matched clinical controls
were tested. At 95% speciﬁcity level sensitivity was 67%.
Sensitivity of 95% was observed at a speciﬁcity level of
62%. Sensitivitywas evenly high acrossmajor histological
types and stage groups. The AUC ¼ 0.94 observed in the
testing studywas not statistically different from the result
of the training set (p-value > 0.05).
Conclusions: The combined analysis of the two DNA
methylation markers SHOX2 and PTGER4 can be used to
detect lung cancer in plasma samples with very high
sensitivity at reasonable false positive rate. These ﬁnd-
ings were derived in a training study and conﬁrmed in
this marker validation study. The marker panel is being
used as the basis for the development of a blood-based
lung cancer diagnostic tool with very high sensitivity.
This new diagnostic tool may ultimately show clinical
utility in combination with current imaging techniques
by reducing the false positive rate of such methods and
has the potential for broader applications in deﬁnition of
the at-risk screening population.Control for stochastic sampling
variation and qualitative sequencing
error in next generation sequencing
analysis of KRAS actionable mutationsJiyoun Yeo, Thomas M. Blomquist,
Xiaolu Zhang, Erin L. Crawford,
James C. Willey The University of Toledo Health Sciences
Campus, Toledo, OHBackground: Clinical implementation ofNext-Generation
Sequencing (NGS) for analysis of actionable mutations in
tumor tissues is challenged by poor control for stochastic
sampling, library preparation biases and qualitative
sequencing error. Potential sources of analytical variation
due to stochastic sampling include low number of analyte
copies loaded into library preparation and low number oflibrary amplicons loaded into sequencer. Sequence error
may be introduced by polymerase inﬁdelity during
ampliﬁcation in library preparation and/or sequencing
reaction. Inadequate control for these factors prevents
establishment of reliable lower detection threshold for
measurement of actionable mutations in cancer speci-
mens.We recently developed amultiplex competitive PCR
amplicon method for NGS library preparation that con-
trols for these sources of analytical variation (Blomquist et
al, 2013; Blomquist et al, 2015). Here we describe imple-
mentation of this method to determine lower limits for
reliable measurement of KRAS codons 12 and 13 muta-
tions in clinical samples.
Methods: DNA was extracted from FFPE samples con-
taining KRAS mutation and serially diluted relative to
FFPE-derived DNA without mutation. Each sample DNA
was mixed with a known number of synthetic internal
standard (IS) molecules for KRAS and multiple other
targets, then multiplex PCR-ampliﬁed using primers
spanning a 100 bp region for each target, including the
KRAS region containing codons 12 and 13 (nucleotide
positions 34-39). The PCR product for each sample was
then loaded onto a Fluidigm AccessArray and each target,
including KRAS, was ampliﬁed in a second round with
single target primers. Each second round PCR product
was loaded onto an Illumina HiSeq. Total KRAS molecule
copies (i.e., wild-type and mutated) were measured in
each sample relative to the known number of synthetic
internal standard copies. Conﬁdence limits for each value
(percent mutated) were calculated based on an equation
that controlled for number of copies loaded into library
preparation and library amplicons loaded into sequencer.
Technically-derived qualitative sequencing errors (i.e.,
base substitution, insertion and deletion) were measured
at each codon 12/13 base position in both a) KRAS native
template (NT) and b) synthetic IS. We previously deter-
mined that the frequency and type of sequence variation
at each base position within each IS is concordant with
that in respective NTs (r2 ¼ 0.93).
Results: For G>A mutations (e.g. 35-38G>A), the poly-
merase error frequency was about 0.1-0.3%. Thus, the
lower limit for reliable detection of a two-fold difference
would be above 0.5%. In contrast, for G>C mutations
error frequency was <0.01% and as long as 50,000
ampliﬁable KRAS copies are loaded (approximately 500
ng of FFPE sample) into library preparation, and given
sufﬁcient sequencing space/sample ratio, it would be
possible to reliably measure two-fold variation in frac-
tion as low as 0.05% with 95% conﬁdence.
Conclusion: The limit to lower detection of KRAS mu-
tation fraction is determined by a) number of ampliﬁable
mutated copies loaded into library preparation, b) num-
ber of library products loaded into sequencer, c) ratio of
